Protein kinase C: a worthwhile target for anticancer drugs?

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Protein kinase C (PKC) enzymes regulate cell proliferation and differentiation, playing roles in cancer development and invasion.
• PKC is implicated in multidrug resistance (MDR) and P-glycoprotein (Pgp) phosphorylation, making it a potential therapeutic target.
• Bryostatin 1 (PKC agonist) and staurosporine analogs (PKC inhibitors) exhibit antineoplastic properties with varying selectivity.

Purpose of the Study:

• To explore the therapeutic potential of targeting Protein Kinase C (PKC) in cancer treatment.
• To investigate the role of PKC in modulating multidrug resistance (MDR) and its interaction with anticancer drugs.
• To review the clinical progress of PKC-targeting agents like bryostatin and safingol.

Main Methods:

• Review of existing scientific literature on PKC, its role in cancer, and related therapeutic agents.
• Analysis of in vitro and in vivo studies on PKC agonists and inhibitors.
• Examination of data from Phase I clinical trials of bryostatin and safingol.

Main Results:

• Bryostatin 1 demonstrates antineoplastic effects and antitumor activity in clinical trials, with myalgia as a dose-limiting toxicity.
• PKC inhibitors can partially reverse MDR and inhibit Pgp phosphorylation; PKC-alpha overexpression is linked to MDR.
• Safingol enhances chemotherapy-induced apoptosis and shows potential for chemopotentiation in ongoing clinical trials.

Conclusions:

• Targeting PKC offers a promising strategy for cancer therapy, particularly in combination with existing cytotoxic agents.
• PKC modulators may overcome multidrug resistance and enhance the efficacy of chemotherapy.
• Further clinical investigation of PKC-targeting drugs is warranted for their potential in oncology.